INTRODUCTION
Non-convulsive status epilepticus comprises 25% of all cases of status 1, with complex partial status, often regarded as a rare condition, being the most common in adults 2"3. Paradoxical exacerbation of epilepsy by conventional antiepileptic drugs has been reported sporadically for at least the last 30 years 4. Tiagabine, a nipecotic acid analogue, is an investigational antiepileptic drug which inhibits gamma amino butyric acid (GABA) neuronal and glial re-uptake. It is effective in patients with partial seizures, with or without secondarily generalized seizures and has only mild adverse effects on the central nervous system 5. There have been no reports of paradoxical aggravation of seizure control by tiagabine, either in the published literature or in reports to the pharmaceutical company. In this report we describe non-convulsive status epilepticus in three patients treated with tiagabine, in doses of 48 to 60 mg/day, for refractory complex partial seizures in combination with two other antiepileptic drugs.
CASE REPORTS
The three patients reported here comprised three of the six patients who entered the open 1059-1311/96/020153 + 04 $12.00/0 continuation phase of a parallel arm design, double-blind, placebo-controlled, multicentre trial of tiagabine in 15 patients with refractory seizures.
Case 1
This 46-year-old man had experienced complex partial seizures from the age of 21 years. Electroencephalography showed bilateral anterior sharp wave activity, mostly over the left temporal region, and foramen ovale recordings indicated lateralization of the left medial temporal lobe and secondary generalization. Tiagabine was added to the pre-existing combination of carbamazepine 400mg b.i.d., and lamotrigine 200 mg b.i.d, when he was averaging five complex partial seizures a month. Subsequently, the patient's carbamazepine dose was reduced to 400 mg daily when tiagabine was increased to 14 mg t.i.d, and lamotrigine continued in a dose of 400 mg daily. Carbamazepine was then progressively withdrawn, while tiagabine was increased to 16 mg t.i.d, in an attempt to limit lassitude. Three days later the patient was admitted to hospital when he became progressively confused and unresponsive, exhibiting aggressive behaviour, repeated chewing activity and yawning, as well as repeated falls. He was unaware of his surroundings for at least 3 hours on the day of admission. When admitted to hospital he exhibited stereotyped movements, was aggressive and uncooperative, using expletives. Following intravenous administration of 10 mg of diazepam there was an instantaneous change, the patient becoming fully orientated in time, person and place, with cessation of involuntary movements and return of normal responsiveness. Subsequent physical and neurological examination was normal. The patient remembered that he could not find the right words prior to admission when in his confused state, but the day after admission his speech was completely normal, although he did experience one secondarily generalized tonicclonic seizure 20 hours after admission. He made an uneventful recovery and has remained well, experiencing his previous level of seizure frequency, continuing to take a lower dose of tiagabine, 14mg t.i. 
Case 2
This 49-year-old man had a 41 year history of localization-related epilepsy, poorly controlled on previous antiepileptic drug therapy, most recently taking carbamazepine 400 mg t.i.d, and phenytoin 350 mg daily. His seizures were characterized by an aura described as 'giving way' as well as by secondarily generalized convulsive seizures with deterioration in seizure control in the 3 months prior to his entering the open continuation phase of the tiagabine trial. The patient had a long standing left lower motor neurone facial weakness. The EEG recorded a left temporal slow wave abnormality and CT head scan showed cerebral and cerebellar atrophy. Tiagabine 10 mg t.i.d, was added to carbamazepine 400 mg t.i.d. and phenytoin 350 mg daily when his monthly seizure frequency ranged from two to six complex partial and secondarily generalized tonic-clonic seizures. The dose of tiagabine was subsequently increased in steps to 12 mg t.i.d., 16 mg t.i.d, and then to a total daily dose of 54 mg at which time his monthly seizure frequency was four. It was then further increased to 20 mg t.i.d, in combination with carbamazepine 400mg t.i.d, and phenytoin 350 mg per day. Two weeks later the patient's wife noticed that he was unresponsive, with periods of staring blankly for up to one hour and recurrent episodes of disturbed balance and vision, following the increase in tiagabine dose to 60mg per day. The patient subsequently experienced three to four episodes of blank staring, with impaired awareness lasting up to 30 minutes, appearing to be in a world of his own, and there was a cluster of 3 secondarily generalized tonic-clonic seizures over the 3-4 weeks leading up to his admission to hospital, with twitching of the right side of his face and shaking of the right arm, held in a flexed position close to his chest. One week later the patient was admitted through the casualty department of a local hospital because of prolonged seizure activity for 4 hours during which he continued to stare into space for a few minutes followed by rigidity of his shoulder, holding his arms flexed in front of his chest and shaking. He appeared to respond to his wife at times, but at others was unresponsive and aphasic. His pupils were both dilated. This episode lasted two and a quarter hours until he was given diazepam 5 mg intravenously, following which he became normally responsive but complained of tiredness with no memory of the preceding event. Tiagabine was progressively withdrawn over the ensuing week while the patient remained seizure-free in hospital and experienced only two partial seizures during the 3 weeks after leaving hospital. He continued to take phenytoin 350 mg daily and carbamazepine 400 mg t.i.d, and has remained well.
Case 3
This 19-year-old moderately retarded man had a ventricular haemorrhage in the perinatal period with subsequent hydrocephalus, requiring a ventriculo-peritoneal shunt. He had experienced generalized tonic-clonic seizures without any warning, at a frequency of approximately one per month all his life, with clusters of complex partial seizures occurring at weekly intervals. He was being treated with a combination of vigabatrin and lamotrigine when he entered a trial of the investigational drug, tiagabine. The patient was subsequently continued on open-label tiagabine, 12mg three times daily, in combination with lamotrigine, 200 mg twice daily, and vigabatrin 1500mg twice a day, at which time he was averaging 25 complex partial seizures per month. He experienced an episode of twilight state in May 1993, when he tookan accidental overdose of tigabine from which he made an uneventful recovery. Following an increase in tiagabine, from 48 mg/day to 60 mg daily, he experienced 12 episodes of a trance-like state, lasting from 1 to 2 hours during a 4 week period, commencing in November 1993, whilst taking tiagabine, 20mg three times daily, in combination with lamotrigine 200 mg twice a day and vigabatrin, 1500 mg twice daily. The patient's parents considered that they resembled the period following the accidental overdose of tiagabine several months previously. His parents noted that he returned to normal between the episodes and interictally the patient was found to have a normal general physical examination and normal neurological examination.
DISCUSSION
These three patients originally formed part of a multicentre parallel arm, placebo-controlled, double-blind trial of tiagabine versus placebo in 15 patients, six of whom continued on the drug as part of an open dose-ranging trial. They had certain clinical features in common. They were all male with a long history of refractory localizationrelated epilepsy, taking other antiepileptic drugs in combination with tiagabine. All three patients experienced prolonged episodes of unresponsiveness, a type of twilight state, during step-dose increases of tiagabine to maximum doses ranging between 48mg/day and 60mg daily. In two patients the seizure symptomatology was immediately terminated by parenteral benzodiazepine therapy and it did not recur in the third following progressive withdrawal of tiagabine. One patient has continued on tiagabine without any further twilight state episodes, but at a lower dose. In case 1, carbamazepine discontinuation, despite its cautious rate of withdrawal, could have lead to the increase in seizure frequency, associated with lack of adequate antiepileptic efficacy of the continuing drugs, namely tiagabine and lamotrigine, despite their continuation in doses that would be expected to have antielpileptic efficacy.
The following criteria have been recommended for the diagnosis of non-convulsive status epilepticus, namely, impaired consciousness or responsiveness, without convulsions, for at least 60 minutes, and concomitant seizure activity in the EEG entirely different from the interictal EEG pattern ~ and recurrent clinical seizures and continuous altered behaviour 2. No EEG was performed in these cases because the episodes resulted in out of hours admission. However, the clinical picture and response to intravenous diazepam in two of them, and the history from reliable eye witnesses in the third, were consistent with the diagnosis of non-convulsive status epilepticus 1-3. All the episodes of twilight state in these three patients occurred in the context of well documented epilepsy, implying that they were examples of complex partial status which is now being recognized with increasing frequency ~e. There was no previous history of episodes of complex partial status in any of the three.
Paradoxical exacerbation of epilepsy by other antiepileptic drugs has been reported sporadically for at least the last 30 years 4. Increased seizure frequency and precipitation of status epilepticus has been reported for phenytoin 6-8. Exacerbation by carbamazepine has also been reported, particularly in association with acute intoxication 2, and in children with recognized brain damage 9-1~. Characteristically, the seizures involved were mainly 'atypical' absences and minor motor seizures which increased in frequeficy a few days after carbamazepine was started and subsided following its discontinuation 4.
Tiagabine, a nipecotic acid analogue, is an investigational antiepileptic drug which inhibits gamma amino butyric acid (GABA) re-uptake. Its clearance is via hepatic metabolism, without production of active metabolites, with an elimination half-life of 5-8 hours and plasma protein binding of 96%. Tiagabine does not induce hepatic enzyme activity, but its metabolism is enhanced by other enzyme-inducing drugs, reducing its elimination half-life to approximately 2-4 hours. Sodium valproate displaces tiagabine from plasma protein binding sites, but tiagabine does not affect the kinetics of other antiepileptic drugs 5. Interactions with other antiepileptic drugs would not seem to explain our observations. Tiagabine is effective in patients with partial seizures, including secondarily generalized seizures and only mildly adverse effects on the central nervous system have been recognized 5. To date, there have been no reports of paradoxical aggravation of seizure control, either in the published literature or reported to Novo Nordisk by Lassen (pers. comm.).
In summary, we have reported three patients who developed prolonged episodes of twilight state, clinically consistent with non-convulsive status epilepticus, following progressive increase in tiagabine dose to between 48 and 60 mg/day. The aim of this report is to draw the attention of clinicians involved in treating patients with refractory epilepsy to the possibility that antiepileptic drugs may produce paradoxical epileptogenic effects, particularly in patients with certain types of refractory partial epilepsy, who are prone to seizure clustering.
